Data for the paper: ‘Effects of different factors on the efficacy of anti PD-(L)1 monotherapy in patients with advanced non-small cell lung cancer: An observational, retrospective cohort study’
doi: 10.4121/19606378
Effects of sex, age, EGFR mutation status and smoking status on immunotherapy. we showed that the benefits for PFS and OS were similar in male and female, and in younger (< 65 years of age) and older (≥65 years of age) patients. EGFR mutation status and smoking status are two independent influencing factors. Regardless of EGFR mutation status, the ORR and PFS of current-smokers were better than those of never-smokers; The benefits of immunotherapy for other mutant subtypes except 19del, L858R and T790M were similar to those of EGFR wild-type; Former-smokers are a unique population who benefit poor from immunotherapy than never-smokers or current-smokers.
- 2022-04-20 first online, published, posted
- This work was supported by grants B2021348 from the Guangdong Medical Research Foundation and 1202101004 from the President Foundation of Integrated Hospital of Traditional Chinese Medicine, Southern Medical University.
DATA
- 233,100 bytesMD5:
c89cc5428f1f46cecb4eccd2d033d2b8
Figure 1 Case inclusion process.pdf - 2,134,571 bytesMD5:
076943bf5e1fbfea99a6d8e7c8451f61
Figure2.A-J.pdf - 2,179,481 bytesMD5:
7af6ded3ac5dccf6eebb53fa1eaa90ab
Figure3.A-D.pdf - 12,253 bytesMD5:
8ac704be316743791578c29a3aefb776
Table 1- Baseline Characteristics.xlsx - 12,228 bytesMD5:
ddc570b47d86a1bace0f9b597811c548
Table 2- Univariable and Multivariable Analysis.xlsx - 11,002 bytesMD5:
3e9fdf0f28f4235f2b76b48ff130bdf0
Table 3- Clinical benefit.xlsx -
download all files (zip)
4,582,635 bytes unzipped